X4 Pharmaceuticals, Inc
XFORNext catalyst
Mavorixafor
WHIM Syndrome
Get an email about XFOR's next catalysts
Track X4 Pharmaceuticals (XFOR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Mavorixafor Phase 3 Est. Readout
Estimated primary completion for Mavorixafor trial (NCT06056297) in Neutropenia. Topline data typically follows completion by weeks to months.
SourceHow XFOR's past catalysts played out
Market Overview
Stock performance and key metrics
Mavorixafor
WHIM Syndrome
X4P-001
WHIM Syndrome
axitinib
Clear Cell Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mavorixafor | Phase 3 | WHIM Syndrome | - | - |
X4P-001 | Phase 2 | WHIM Syndrome | - | - |
axitinib | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
Frequently asked questions
What is in X4 Pharmaceuticals, Inc's drug pipeline?β
CatalystAlert tracks 3 drug candidates in X4 Pharmaceuticals, Inc's (XFOR) pipeline across Phase 3, Phase 2. Its lead program is Mavorixafor (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is X4 Pharmaceuticals, Inc's next FDA catalyst?β
X4 Pharmaceuticals, Inc's (XFOR) next tracked catalyst is a Phase 3 readout expected September 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XFOR biotech catalysts?β
Add XFOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow X4 Pharmaceuticals, Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
